Purpose: To assess the use of specialised medical epilepsy services by people with learning disabilities (LD) and epilepsy in a community healthcare setting, to compare medical epilepsy care in this group to current management guidelines, and to contrast important outcomes with those achieved in different healthcare settings. Methods: Postal survey with a carer completed questionnaire addressed to all adults with epilepsy registered on an LD register in Sheffield, UK (n = 442). Results: An analysis based on 225 returned questionnaires revealed that 22.7% of individuals with LD and epilepsy had been free of seizures for over 1 year. 95.1% were taking antiepileptic drugs (AEDs), 46.2% had had an EEG, and 41.3% a brain scan. 53.3% of diagnoses had been made by epilepsy experts, 38.7% of individuals with LD and epilepsy were under specialist review. Although patients with more severe epilepsy were more likely to be under specialist care, 60.6% of patients with ongoing seizures,
In the last decade, the provision of community and hospital medical services has undergone rapid changes in many developed countries. In the UK, a number of recent healthcare reforms were intended to reduce the role of costly (and typically hospital-based) specialist service providers and to increase the scope of community medical services. As traditional referral routes and treatment responsibilities are redesigned and redistributed, ''patient journeys'' have become a particular focus of interest. Ideally, historical arrangements would not only be replaced by less expensive systems, but also by organisational structures, which would lead to improvements in the selection of patients referred to specialist services. This would focus limited specialist care resources on those patients who could benefit most.
Optimal ''patient journeys'' probably matter most in conditions or situations where patients may not be able to seek out the most appropriate services for themselves, for instance in the area of healthcare provision for people with learning disabilities (LD).
In some ways, the disestablishment of specialised LD residential care facilities has led the way for changes in many other areas of healthcare provision. For instance, in one area in the UK, 54% of people with LD lived in specialist hospital accommodation in 1983, and only 6% in 1995. 1 This means that the examination of an established model of community care for people with LD may offer important insights into the potential benefits and pitfalls of similar healthcare delivery models in other areas.
The arrangements put in place for people with LD in Sheffield, UK, in the 1970s placed particular emphasis on the integration of people with LD into general healthcare services. In this model, most medical care needs are addressed in a community setting, and the General Practitioner (GP) becomes the primary medical point of contact. Usual care is supplemented by multidisciplinary Community Learning Disability Teams covering certain geographical areas and consisting of physiotherapists, occupational therapists, psychologists, speech and language therapists, social workers and specialist nurses in LD. Although these teams have no direct referral rights to epilepsy specialist services they are intended to ensure that all of the patients' healthcare needs are met, using the GP to secure access to specialist advice if necessary. The Community Learning Disability Teams belong to the Joint Learning Disabilities Service (JLDS), which is part of the community mental health service. It retains a small medical LD service staffed with one psychiatrist with an interest in LD and a seven-bedded assessment and treatment unit (ATU) with a primarily psychiatric focus. It is the remit of the ATU to provide assessment and treatment of individuals with significant LD with challenging behaviour or comorbid psychiatric disorders. There is no access to EEG or video-telemetry. The JLDS also has access to five beds on a general psychiatric ward for people with mental disorders and less severe LD. Finally there are 15 designated beds for individuals with LD and complex health needs, which form the health component of an integrated respite service.
The hospital-based specialist epilepsy service consists of four consultant neurologists with access to relevant investigations including magnetic resonance imaging under general anaesthesia and epilepsy specialist nurses (who will only advise patients under the current care of a neurologist). Although the National Health Service is essentially the only purchaser of medical services for individuals with LD, the healthcare providers described here belong to different organisation with independent budgets (community mental health services, medical hospital services and several primary care organisations). The introduction of this model of community care was supported by a database (Sheffield Case Register) held by the local provider of mental health services which shares information with social and educational services and contains details of people with more severe LD.
We conducted a postal survey to find out more about the health services utilisation of people with LD and epilepsy on the Sheffield Case Register, and how service use relates to current management guidelines for epilepsy. 2, 3 We also examined whether patients with the greatest need have Epilepsy care for people with learning difficulties 85 57.9% with major seizures and 68.7% of individuals taken to hospital with prolonged had no access to specialist advice.
Conclusion:
The proportion of people with LD who achieved seizure-control in the described population was lower than in all previously reported studies of LD patient groups. The poor outcome in terms of seizure-control, the lack of access to the epilepsy specialist service, and the apparent under-utilisation of investigations indicate that there are grounds for serious concern about this community model of medical epilepsy care for people with LD. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
access to the local specialist epilepsy services. Finally, we assessed the quality of epilepsy services for people with LD and epilepsy by comparing treatment outcomes in Sheffield residents with those in similar populations treated in other healthcare settings.
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Methods and patients
The findings of this survey are based on an ''Epilepsy Questionnaire'' specifically designed for this study by a multidisciplinary group comprising social services managers, nurse specialists in epilepsy and learning disabilities, and a neurologist with a particular interest in epilepsy. The survey was approved as a service evaluation by the clinical audit department of the Sheffield Care Trust. The questionnaire was designed to be completed by carers for people with LD. It contained a total of 19 closed questions. Answers were elicited in tick-boxes. The questionnaire was sent to all individuals from the Sheffield Case Register who also had a recorded diagnosis of epilepsy. The Register contains details of people with LD who meet at least one additional criterion (in need of a developmental curriculum, regular users of LD services, clinical condition which is a recognised cause of LD, requiring support from residential, day or community services because of LD). Individuals with a diagnosis of mild mental retardation (IQ 50-70) are not registered. At the time of the study the register contained details of 1934 Sheffield residents with LD above the age of 18. An additional diagnosis of epilepsy was recorded in 442. The diagnoses of LD and epilepsy had been made by a doctor in primary or secondary care. The questionnaire was piloted in 10 individuals. The questionnaire was only sent out once. No attempts were made to remind or chase up nonresponders. Questionnaires were only analysed if the person completing the questionnaire confirmed the diagnosis of epilepsy on the questionnaire.
Variables were compared using the x 2 -test. A two-tailed p < 0.05 was considered significant.
Results
The questionnaire was addressed to 442 adults with LD and epilepsy living in Sheffield, UK. The mean age was 43.5 (SD 16.1, range 18-86 years), 53.3% of addressees were male, the most frequently represented ethnic groups were White (91.2%), Pakistani (3.9%) and Black (0.9%). 44.6% lived in residential care or supported living, 43.2% with carers, 6.9% on their own, 1.2% were married or living with a partner, residential arrangements were unknown for 4.2%. Questionnaires providing information on 236/ 442 (53.4%) people with LD and epilepsy were returned. The diagnosis of epilepsy was denied on eleven questionnaires, this analysis is thus based on 225/442 returns (50.9%).
Description of seizure disorders
Sixty percent of people with LD and epilepsy were reported as having had ''major seizures'' in the last year (described in the questionnaire as ''for example blacking out, going stiff and jerking, falling down''). 62.7% had ''minor seizures'' (''for example funny turns, blank spells, confusion''). Only 22.7% had not had any seizures over the last year (Fig. 1 ). 15.6% had to attend a hospital Accident and Emergency Department at least once over the preceding year because seizures would not stop, 5.3% attended more often. 34.2% of respondents reported seizures from sleep, 28.0% denied sleeprelated seizures, and 37.8% stated that they were unsure about seizures from sleep.
Antiepileptic drug treatment
The number of antiepileptic drugs (AEDs) used as regular medication by individuals with LD and epilepsy ranged from nil to five (median 1). 4.9% of people with LD and epilepsy were described as not taking any of the listed AEDs, 48.4% were receiving AED monotherapy, 46.7% AED combination therapy. The most commonly used drugs were carbamazepine (50.2%), sodium valproate (39.6%), phenytoin (18.2%), levetiracetam (13.3%), lamotrigine (8.4%), phenobarbitone (6.7%), clobazam (5.8%), topiramate (5.8%). Acetazolamide, clonazepam, ethosuximide, gabapentin, oxcarbazepine, pregabaline, tiagabine, vigabatrin and zonisamide were also used Figure 1 Frequency distribution of ''major'' and ''minor'' epileptic seizures over the preceding year in 225 adults with LD in epilepsy. Only 22.7% had been completely seizure-free for at least 1 year.
but by less than 5% of individuals. 26.2% received one of the pharmacological agents licensed for use in the UK since 1993 (described as ''newer'' AEDs in recent epilepsy guidelines).
14 Of the 27.6% of respondents who had a supply of rectal diazepam, buccal midazolam or both at home to interrupt prolonged seizures (27.4% diazepam, 4.5% midazolam), only 42.6% stated that they had received training from a nurse or a doctor on how to give this medication. Only 40% of carers of those individuals with LD and epilepsy who had been to Accident and Emergency over the last year with a prolonged seizure had access to emergency medication.
Interaction with general and specialist health services 53.3% of epilepsy diagnoses had been made by a seizure expert (neurologist or paediatrician). 46.2% of residents stated that the person with LD and epilepsy had had an EEG, and 41.3% that a brain scan had been performed. 68.9% of respondents agreed that the individual had been assessed by an expert in secondary care (neurologist, psychiatrist or epilepsy nurse) at some point. 60.4% had seen a neurologist, 34.2% an epilepsy nurse, and 20.9% a psychiatrist. 70.7% stated that there had been an epilepsy treatment review within the last 12 months, the remaining respondents said reviews were carried out less frequently. 38.7% of individuals with LD and epilepsy were reported to be under review in secondary care (neurologist, psychiatrist or epilepsy nurse), 52.9% stated that reviews were carried out in primary care alone and 8.9% said that epilepsy treatment had not been reviewed at all. Only 23.4% of respondents said they were aware of the existence of a local Epilepsy Action group although this group has existed since 1985 (Epilepsy Action is the largest epilepsy selfhelp organisation in the UK). Table 1 cross tabulates indicators of access to regular or specialist epilepsy advice with markers of epilepsy complexity. Table 2 shows a cross tabulation of indicators of seizure severity and epilepsy service input.
Discussion
A range of studies have suggested that the prevalence of LD in the population is around 0.5%. 15 Whereas epilepsy occurs in around one in 200 individuals in the general population, the prevalence of epilepsy in people with LD has been estimated as between one in four and one in five. 15 Although other socioeconomic and biological factors play an important role, 16 the prevalence of epilepsy increases with the degree of intellectual impairment and motor disability. However, the risk of epilepsy depends most strongly on the particular aetiology of LD. 10, 12, 15, 17 Reports from a range of sources in the UK suggest that LD registers have captured the population of residents with LD increasingly well over the last 50 years. 18 Given that the Sheffield LD register is intended to capture all people with moderate or severe LD from a resident population of 413,000 adults, contains information on 1934 people with LD and identifies 433 with a diagnosis of epilepsy, it appears that the participants in our survey were identified from a reasonably complete source.
The responses to the questionnaire suggest that the use of specialist epilepsy services and epilepsyrelated investigations in the described population of people with LD and epilepsy fell significantly short of published national and international consensus guidelines for the management of the epilepsies in adults. 2, 3 The recommendations in the guidelines of the UK National Institute of Clinical Excellence (NICE) are graded according to the level of supporting evidence (see Table 3 ). The guidelines specifically state that ''people with epilepsy who have LD should receive the same support and care as the general population'' (GPP). In recognition of the particular difficulties which clinicians may face when diagnosing or treating patients with LD and epilepsy, [19] [20] [21] [22] [23] the guidelines state that ''the diagnosis of epilepsy should be made by an expert in the epilepsies'' (C). According to our results, just over half of all diagnoses had been made by an epilepsy expert. The guidelines also recognise the particular challenges involved in the ongoing management of people with LD and epilepsy, such as increased levels of psychopathology, behavioural problems, sideeffects of antiepileptic drugs and carer distress. 18, [24] [25] [26] Although the guidelines recommend that ''the management and treatment of epilepsy in a person who has LD should be undertaken by a specialist, working within a multidisciplinary team'' (C), just over one-third stated that their epilepsy was under continuing review by an epilepsy specialist in secondary care. One particular reason why it might be important for people with LD and epilepsy to be assessed by specialists in secondary care is that access to investigations such as electro-encephalography (EEG) (C), video-EEG (C) (considered essential in the national guidelines) is often restricted to specialists. Less than half of the respondents to this survey thought that any EEG investigation had been carried out. Even fewer people with LD and epilepsy appear to have had brain imaging although the guidelines recommend the use of ''neuroimaging (MRI/CT) to identify structural abnormalities that cause certain epilepsies'' (C). The only situation in which neuroimaging is not recommended in the evaluation of people with epilepsy is ''when a diagnosis of idiopathic generalised epilepsy has been made'' (C). Neuroimaging (especially MRI) should be considered particularly important in the context of LD because it may not only reveal the cause of epileptic seizures but also establish the aetiology of LD, potentially leading to appropriate further screening and care (such as in neurofibromatosis or tuberous sclerosis) 27 or genetic diagnoses enabling testing and genetic counselling of potential carriers (for instance in cortical malformation disorders). 28 Annual (or more frequent) epilepsy treatment reviews (as suggested by the guidelines (D)) were only reported by two thirds of respondents.
We can only speculate why specialist services and investigations were under-utilised. There were no formal barriers to the referral of patients with LD and seizures to the specialist service. Further research seems justified to find out whether the low utilisation rates were related to the choices of individuals with LD, low expectations of general practitioners and carers, a perceived need to protect scarce healthcare resources, practical difficulties associated with the attendance of hospital-based clinics or other reasons. Notably, almost one half of the individuals under specialist care reported that they had not had neuroimaging or an EEG.
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M. Reuber et al. Table 1 shows that specialist care and a higher review frequency were not allocated randomly but offered to patients with more severe epilepsies. However, the cross tabulation also reveals that over 60% of patients with ongoing seizures, nearly 60% with major (probably tonic clonic) seizures and two thirds of the patients who had been taken to hospital with prolonged seizures had no access to specialist advice. Only one in 10 patients under primary care review was taking one of the ''newer'' antiepileptic drugs although recent studies suggest that the use of these drugs can be very beneficial in patients with LD. 3, 29 Whilst the use of these AEDs is not guaranteed to lead to an increase in the number of people with LD who become seizure-free, 30 the drugs have been recommended for use in national treatment guidelines if seizures prove refractory to ''standard'' AEDs. 14 The cross tabulation of indicators of seizure severity and epilepsy service input (Table 2 ) reveals that patients with more severe and more frequent seizures were more likely to be treated with ''newer'' AEDs or combination therapy. However, less than 40% of those patients who had been taken to hospital with a prolonged seizure over the last year had access to emergency medication, and there was no indication that patients with particularly troublesome seizure disorders were more likely to have been investigated with neuroimaging or EEG. Given that patients under expert review were more likely than patients under primary care review to have had neuroimaging (see Table 1 ) this may be a reflection of the fact that only a minority of patients (even of those with refractory seizures) were seen by epilepsy experts.
Although achieving full seizure control is only one of many relevant positive outcomes in the lives of people with LD and epilepsy, 31 seizure-freedom is an important treatment target and, once achieved, can be maintained in over 80% of individuals. 4 What is more, reports of seizure-freedom are likely to be relatively reliable and full seizure control captures additional benefits such as a lower risk of seizurerelated injuries and sudden unexplained death in epilepsy (SUDEP), 32 reduced risk of psychiatric comorbidity and carer anxiety, facilitation of school, work or care arrangements. 18 The proportion of individuals who achieve full seizure control is also a measure, which allows a comparison between an important treatment outcome of one LD epilepsy care model with another (Table 4) .
In terms of this outcome measure, the integration-oriented model examined here seemed to perform much less well than any other healthcare delivery model described in the recent literature. This is all the more striking as many of the previous studies were based on more selected populations likely to have included a higher proportion of people with severe and refractory epilepsies (for instance residents in specialist institutions or attendants of specialist clinics). In fact, the available evidence suggests that, with optimal medical care, at least 40% of unselected patients with LD and epilepsy should become seizure-free. 4, 6 Of course, this study has a number of limitations. Our findings are based on questionnaires completed by carers. It is possible that respondents misunderstood some of the questions, rated non-epileptic paroxysmal behaviours as manifestations of ongoing epilepsy or failed to recollect tests, treatment reviews or visits to specialists. It is conceivable that carers were more likely to return the questionnaire if the person with LD and epilepsy in their care continued to have seizures or if they were unhappy with the care they had received. Lastly, our analysis is based on a very limited dataset, because we wanted to ensure that our questionnaire was as simple to complete as possible.
However, the extremely poor outcome in terms of seizure-control (even compared to studies using a similar methodology or studies focussing on people with more severe disabilities) means that there are grounds for serious concern about the fragmentation of healthcare services for people with LD, the lack of access to the epilepsy specialist service, apparent under-utilisation and suboptimal targeting of investigations, irregular critical treatment reviews, and low levels of use of ''newer'' antiepileptic drugs. The poor access to optimal care for people with LD and epilepsy evident from these results may represent a manifestation of institutional neglect, 33 which has been identified in many other areas of healthcare for people with disabilities. 34, 35 Another study from the UK recently demonstrated that expert review of individuals with epilepsy (but no LD), who had not had access to specialist advice, led to alternative diagnoses in 18.9%, and to the achievement of seizure control in 30.9% of the patients with active epilepsy. 36 Unfortunately, epilepsy experts are a very limited resource in the UK. Although it is improbable that major improvements could be achieved without an expansion of specialist services, it may be more realistic in the short term for healthcare providers to fulfil their legal obligations under a new statutory ''disability equality duty'' by focussing on improving referral pathways or on developing assessment instruments which could help relatively inexperienced healthcare staff to refer on those individuals with LD and epilepsy who could benefit most from expert assessment or investigations. 37 Importantly, such tools should not only identify individuals with the most severe seizure disorders. The cross tabulations used in this report could help to monitor the effectiveness of policy changes.
